Compare ACM Research Inc (ACMR) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACM Research Inc vs Inovio Pharmaceuticals Inc — how do they compare? ACM Research Inc trades at $98.07 (market cap $6.54B), while Inovio Pharmaceuticals Inc trades at $1.22 (market cap $99.55M). The key difference: ACM Research Inc is far larger — about 65.7× Inovio Pharmaceuticals Inc's market cap, and ACM Research Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ACMR | INO | |
|---|---|---|
Market Cap | $6.54B | $99.55M |
Sector | Technology | Health |
52-Week High | $126.89 | $2.87 |
52-Week Low | $23.92 | $1.05 |
Enterprise Value | $5.61B | $70.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACMR trades at $98.52, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $110. Recent earnings showed a Q1 2026 beat but misses in prior quarters. Revenue grew to $901 million in 2025, though net income margins are under pressure. The stock has experienced volatility, with news highlighting semiconductor sector catalysts and a GF Score of 82 (GuruFocus, June 25, 2026).
Outlook is positive with 80% analyst buy ratings and semiconductor demand tailwinds, but risks include earnings inconsistency, high valuation multiples, and negative operating cash flow. Investors should weigh growth potential against execution risks in a competitive market.
INO trades at $1.21, down 2.02% today, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company shows minimal revenue of $65,340 (2025) with significant losses (-$84.95M net income), though recent earnings beats and FDA review of INO-3107 (PDUFA date October 30, 2026) provide catalysts. Analyst consensus is 53% buy, but multiple class action lawsuits pose legal risks.
Outlook hinges on FDA approval of INO-3107, which could drive upside, but high cash burn (-$21.54M net cash flow in 2025) and negative margins (-130,000% net income margin) underscore substantial operational risks. Investors face a binary event-driven opportunity with elevated volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACM Research Inc
ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.
Read more on ACMR →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
